SSRI Dosing in Body Dysmorphic Disorder
OCD's own high-dose SSRI philosophy is well established — the real question here is whether body dysmorphic disorder, a related but genuinely distinct diagnosis, actually needs the same ceiling or an even higher one.
E.V., a 23-year-old woman, works in retail at a clothing store and has recently begun avoiding shifts that involve the store's brightly lit fitting-room area, citing scheduling conflicts to her manager that aren't real. She lives with a roommate and has no significant medical history.
She was diagnosed with body dysmorphic disorder five months ago, centered on a perceived asymmetry in her nose that she describes as "obvious to everyone" despite reassurance from friends and family that nothing about her appearance stands out. She spends over three hours daily checking mirrors and photo filters, has requested two consultations for rhinoplasty that her insurer declined to cover, and has started avoiding social events entirely rather than be photographed. Her BDD-YBOCS today is 32, severe range. She was started on fluoxetine 20 mg six weeks ago by her primary care physician, with no improvement, and was referred to psychiatry today for dose guidance.
BDD sits in the same DSM-5 chapter as OCD and shares real neurobiological and treatment overlap, which has led many clinicians to reasonably extend OCD's high-dose SSRI philosophy to BDD by default. But the actual dosing evidence for BDD is its own, separate body of literature, not a borrowed extrapolation — and if anything, several controlled trials and expert consensus guidelines suggest BDD may require doses at or even above OCD's own already-elevated ceiling, with some patients needing fluoxetine up to 80 mg or its equivalent in other SSRIs before showing meaningful response, and trial durations that run at least as long as OCD's twelve-week window, sometimes longer given BDD's documented tendency toward slower symptom resolution. The question in front of the group isn't whether to raise her dose — it's whether to treat "OCD-level" as the actual ceiling or as a floor that BDD's own evidence suggests she may need to exceed.
Setting BDD's own dose ceiling, not OCD's borrowed one
I want to correct a framing before we set her target: this isn't "apply OCD's high dose to BDD," it's "apply BDD's own dose evidence," which happens to run at or above OCD's ceiling in several controlled trials. Fluoxetine up to 80 mg, or equivalent doses of other SSRIs, is well within BDD's own evidence base, not an extrapolation borrowed from a different diagnosis. I'd titrate her toward 80 mg, not stop at OCD's typical 60.
Agreed on the target, and I'd add that her poor insight matters for how we frame the conversation with her, not for the dose itself — she doesn't experience her nose concern as excessive the way many OCD patients recognize their compulsions as excessive even while performing them. That doesn't change the pharmacology, but it does mean I'll spend more time on the rationale for medication than I would with a typical OCD referral, since she isn't arriving already convinced something is wrong that needs treating.
I'd also flag the trial-length side of this clearly in her chart, since BDD's documented tendency toward slower symptom resolution means twelve weeks at target dose should be treated as a floor, not an automatic endpoint for judgment the way it might be read elsewhere. If she's still improving gradually at week twelve, that's a reason to continue, not to conclude the trial has run its course.
Agreed: fluoxetine titrated toward 80 mg over the coming weeks, with a BDD-YBOCS recheck planned at week twelve from reaching target dose, explicitly framed as a floor for continued evaluation rather than an automatic cutoff given BDD's slower documented response curve.
The group also agreed to document the dosing rationale explicitly as BDD's own evidence base, not an OCD extrapolation, so a future provider reviewing her chart understands why her target sits above what an OCD referral would typically list.